Moment of Clarity Publishes Comprehensive New Resource on Website Discussing Steps in Spravato Treatment for Recovery

RESEDA, CA - March 20, 2026 - PRESSADVANTAGE - Moment of Clarity has released a detailed educational resource outlining ...

Moment of Clarity Publishes Comprehensive New Resource on Website Discussing Proper Spravato Dosing During Treatment and Clinical Oversight Standards

SANTA ANA, CA - March 16, 2026 - PRESSADVANTAGE - Moment of Clarity has published a new educational resource detailing ...
The Florida Times-Union

Moment of Clarity Publishes New Resource Detailing How Spravato Supports Bipolar Depression Treatment

Moment of Clarity has published a new educational article titled “Spravato for Bipolar Depression Treatment“, providing an in-depth exploration of how esketamine therapy is being used to manage ...
Nasdaq

SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression

TITUSVILLE, N.J., Jan. 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for ...